Loading clinical trials...
Loading clinical trials...
A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of Cedirogant (ABBV-157) in Adult Subjects With Moderate to Severe Psoriasis
Conditions
Interventions
Cedirogant
Placebo
Locations
53
United States
UAB Department of Dermatology /ID# 238563
Birmingham, Alabama, United States
Medical Dermatology Specialist /ID# 238518
Phoenix, Arizona, United States
Arkansas Research Trials, LLC /ID# 238687
North Little Rock, Arkansas, United States
Encino Research Center /ID# 245950
Encino, California, United States
Velocity Clinical Research, Inc. /ID# 239536
North Hollywood, California, United States
Medderm Associates /ID# 238834
San Diego, California, United States
Start Date
November 16, 2021
Primary Completion Date
November 30, 2022
Completion Date
November 30, 2022
Last Updated
November 29, 2023
NCT06857942
NCT06979453
NCT07449234
NCT07116967
NCT07250802
NCT07449702
Lead Sponsor
AbbVie
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions